Showing results (21-30 of 32) with videos related to
Sort By:
Pageof 4
Therapeutic Drug Monitoring|September 23, 2008
Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patientsCaroline Solas, Marie-Claude Gagnieu, Isabelle Ravaux, et al.AIDS Research and Therapy|April 5, 2016
Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trialNathalie de Castro, Joséphine Braun, Isabelle Charreau, et al.HIV Clinical Trials|February 11, 2003
Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal studyAlain Lafeuillade, Nathan Clumeck, Josep Mallolas, et al.AIDS (London, England)|May 15, 2010
Hepatitis E virus in HIV-infected patientsChristophe Renou, Alain Lafeuillade, Jean-François Cadranel, et al.Journal of Virus Eradication|July 28, 2018
Highlights from the 20th International Symposium on HIV and Emerging Infectious Diseases (ISHEID) 16-18 May 2018, Marseille, France: from HIV and comorbidities to global healthChristina Psomas, Sabine Kinloch, Caroline Sabin, et al.Antiviral Therapy|May 14, 2003
Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trialSophie Matheron, Diane Descamps, François Boué, et al.Clinics and Research in Hepatology and Gastroenterology|July 19, 2014
Impact of IL28B on the treatment decision in naïve and experienced patients with genotype 1 and 4 chronic hepatitis C in real-life clinical practice: a prospective multicenter cohortPhilippe Halfon, Denis Ouzan, Tarik Asselah, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|June 28, 2005
Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patientsClotilde Allavena, Virginie Ferré, Cécile Brunet-François, et al.British Journal of Clinical Pharmacology|March 18, 2004
Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitorCaroline Solas, Isabelle Poizot-Martin, Marie-Pierre Drogoul, et al.The Lancet. Infectious Diseases|February 22, 2015
Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trialAntoine Chéret, Georges Nembot, Adeline Mélard, et al.Pageof 4